Skip to main content

Table 2 Clinical trials of CD19-directed CAR-T cells in China

From: Clinical trials of CAR-T cells in China

Target antigen Diseases CAR Vector NCT no.
CD19 Leukemia, lymphoma 4-1BB- CD3ζ RV NCT01864889
CD19 B cell malignancies CD28, CD137, CD27 LV NCT03050190
CD19 MCL 4-1BB-CD3ζ RV NCT02081937
CD19 Leukemia NA NA NCT03142646
CD19 B cell lymphomas CD27-CD3ζ LV NCT02247609
CD19 Leukemia, lymphoma NA NA NCT02349698
CD19 Elderly relapsed/refractory B cell ALL NA NA NCT02799550
CD19 Leukemia, lymphoma NA NA NCT02537977
CD19 B cell leukemia NA NA NCT02644655
CD19 B cell leukemia and lymphoma NA NA NCT02813837
CD19 B cell lymphoma NA NA NCT02547948
CD19 B cell lymphoma CD28-CD3ζ RV NCT02652910
CD19 Leukemia, lymphoma CD28, CD3ζ LV or RV NCT02456350
CD19 Recurrent or refractory acute non-T-lymphocyte leukemia NA NA NCT02735291
CD19 Lymphoma NA NA NCT02728882
CD19 Leukemia, lymphoma NA NA NCT02546739
CD19 B cell lymphomas NA NA NCT02842138
CD19 ALL NA NA NCT02810223
CD19 ALL CD28-CD137-CD3ζ LV NCT02186860
CD19 B cell leukemia, B cell lymphoma CD3ζ, CD28, and 4-1BB LV NCT02963038
CD19 NHL TCRζ, 4-1BB LV NCT03029338
CD19 B cell ALL TCRζ, 4-1BB LV NCT02975687
CD19 B cell leukemia and lymphoma NA LV NCT02933775
CD19 B cell leukemia 4-1BB LV NCT02672501
CD19 Central nervous system B cell acute lymphocytic leukemia NA NA NCT03064269
CD19 ALL 4-1BB LV NCT02965092
CD19 Acute leukemia NA NA NCT02822326
CD19 Leukemia, lymphoma CD28 or 4-1BB and a CD3ζ LV or RV NCT03076437
CD19 Leukemia and lymphoma NA NA NCT02851589
CD19 Leukemia and lymphoma NA NA NCT02819583
CD19 DLBCL NA LV NCT02976857
CD19 Recurrent or refractory B cell malignancy NA NA NCT02782351
CD19 Leukemia and lymphoma TCRz-CD28, TCRz-CD137 NA NCT02685670
CD19 B cell lymphoma 4-1BB, CD3ζ NA NCT03101709
CD19 ALL NA NA NCT02924753
CD19 ALL NA NA NCT03027739
CD19 B cell leukemia NA LV NCT02968472
CD19 B cell lymphoma CD28ζ NA NCT02992834
CD19 AML NA NA NCT03018093
CD19 Systemic lupus erythematosus 4-1BB LV NCT03030976
CD19 NHL NA LV NCT03154775
CD19 Lymphoma NA NA NCT03086954
CD19 ALL, CLL, lymphoma CD28 or 4-1BB and CD3ζ NA NCT03191773
CD19 B cell lymphoma 4-1BB-CD28-CD3 NA NCT03146533
CD19 Leukemia NA NA NCT03173417
CD19 Relapsed or refractory B cell lymphoma 4-1BB LV NCT03208556
CD19 B cell leukemia and lymphoma    NCT03166878
CD19 B cell lymphoma NA NA NCT03118180
CD19 or CD20 Relapse/refractory B cell malignancies NA LV NCT02846584
CD19 and CD20 DLBCL NA NA NCT02737085
CD19 and CD22 Hematopoietic/lymphoid cancer TCRζ, 4-1BB NA NCT02903810
CD19/CD20 B cell leukemia and lymphoma CD3ζ, 4-1BB-CD3ζ RV NCT03097770
CD19/CD22 B cell malignancy NA RV NCT03185494
CD19/CD22 B cell leukemia, B cell lymphoma NA LV NCT03098355
CD19/CD20/CD22/CD30 B-NHL NA NA NCT03196830
CD19/CD20 B cell malignancy NA NA NCT03207178
CD19 and CD20/CD22/CD38/CD123 B cell malignancy NA LV NCT03125577
  1. AMMS Academy Military Medical Sciences, ALL acute lymphoblastic leukemia, AML acute myeloid leukemia, BCMA B cell maturation antigen, CTX cyclophosphamide, DLBCL diffuse large B cell lymphoma, FLU fludarabine, HL Hodgkin’s lymphoma, LV lentiviral, MCL mantle cell lymphoma, NA not available, NHL non-Hodgkin lymphoma, RV retroviral, TCM traditional Chinese medicine